JP2022502495A5 - - Google Patents
Info
- Publication number
- JP2022502495A5 JP2022502495A5 JP2021540390A JP2021540390A JP2022502495A5 JP 2022502495 A5 JP2022502495 A5 JP 2022502495A5 JP 2021540390 A JP2021540390 A JP 2021540390A JP 2021540390 A JP2021540390 A JP 2021540390A JP 2022502495 A5 JP2022502495 A5 JP 2022502495A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- positions
- seq
- acid sequence
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736293P | 2018-09-25 | 2018-09-25 | |
| US62/736,293 | 2018-09-25 | ||
| US201962903592P | 2019-09-20 | 2019-09-20 | |
| US62/903,592 | 2019-09-20 | ||
| PCT/US2019/052784 WO2020068867A1 (en) | 2018-09-25 | 2019-09-24 | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502495A JP2022502495A (ja) | 2022-01-11 |
| JP2022502495A5 true JP2022502495A5 (enExample) | 2022-10-03 |
Family
ID=68165800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540390A Pending JP2022502495A (ja) | 2018-09-25 | 2019-09-24 | チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11034672B1 (enExample) |
| EP (1) | EP3856726A1 (enExample) |
| JP (1) | JP2022502495A (enExample) |
| KR (1) | KR20210137422A (enExample) |
| CN (1) | CN113382986A (enExample) |
| AU (1) | AU2019346550A1 (enExample) |
| BR (1) | BR112021005513A2 (enExample) |
| CA (1) | CA3113241A1 (enExample) |
| IL (1) | IL281805A (enExample) |
| MX (1) | MX2021003517A (enExample) |
| SG (1) | SG11202102981SA (enExample) |
| WO (1) | WO2020068867A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210137422A (ko) | 2018-09-25 | 2021-11-17 | 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 | 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도 |
| CN119390683A (zh) | 2019-08-15 | 2025-02-07 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| WO2021195206A1 (en) * | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| TWI782504B (zh) * | 2020-05-08 | 2022-11-01 | 美商美國禮來大藥廠 | (三氟甲基)嘧啶-2-胺化合物 |
| WO2022006386A1 (en) * | 2020-07-02 | 2022-01-06 | Enliven Therapeutics, Inc. | Alkyne quinazoline derivatives as inhibitors of erbb2 |
| CA3188077A1 (en) * | 2020-08-10 | 2022-02-17 | Fei Yang | Egfr inhibitor, preparation method therefor and application thereof |
| WO2022040377A1 (en) | 2020-08-20 | 2022-02-24 | Black Diamond Therapeutics, Inc. | Methods for preparing quinazoline derivatives |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| WO2022076671A1 (en) * | 2020-10-08 | 2022-04-14 | Black Diamond Therapeutics, Inc. | Method of treating cancers using quinazoline derivatives |
| CN116710096A (zh) * | 2020-11-02 | 2023-09-05 | 黑钻治疗公司 | 用炔取代的喹唑啉衍生物治疗癌症的方法 |
| TWI910256B (zh) * | 2020-11-02 | 2026-01-01 | 美商黑鑽醫療公司 | 使用經炔取代之喹唑啉衍生物類以治療癌症之方法 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN116655599B (zh) * | 2023-05-17 | 2025-07-29 | 江南大学 | 一类egfr别构抑制剂的合成及其用途 |
| EP4724436A1 (en) * | 2023-06-12 | 2026-04-15 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2025096300A1 (en) * | 2023-10-30 | 2025-05-08 | Eli Lilly And Company | Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives |
| CN118084767B (zh) * | 2024-04-02 | 2025-06-17 | 康龙化成手性医药技术(宁波)有限公司 | 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法 |
| CN118652239A (zh) * | 2024-05-29 | 2024-09-17 | 江南大学 | 一类egfr别构抑制剂的合成及其用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| YU90901A (sh) | 1999-06-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg. | Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| CA2403152C (en) | 2000-04-08 | 2008-10-28 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10042061A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| BR0214606A (pt) | 2001-11-30 | 2004-09-14 | Pfizer Prod Inc | Processos para a preparação de derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal |
| BR0307544A (pt) | 2002-02-01 | 2004-12-07 | Ariad Gene Therapeutics Inc | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos |
| JP4201716B2 (ja) | 2002-03-05 | 2008-12-24 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害剤 |
| DE10217689A1 (de) | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| US20070032513A1 (en) | 2003-09-16 | 2007-02-08 | Hennequin Laurent F A | Quinazoline derivatives |
| AP2204A (en) | 2004-05-06 | 2011-02-07 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides. |
| KR20200019263A (ko) | 2004-09-02 | 2020-02-21 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| WO2007055513A1 (en) | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
| US8604044B2 (en) | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| EP2331530B8 (en) | 2008-09-26 | 2013-12-25 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| CN105037333A (zh) * | 2009-12-21 | 2015-11-11 | 张强 | 新的喹唑啉衍生物 |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| CN102382065B (zh) | 2010-08-30 | 2014-05-28 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| CN102452989B (zh) | 2010-10-19 | 2014-10-22 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| KR102061743B1 (ko) | 2011-03-04 | 2020-01-03 | 뉴젠 세러퓨틱스 인코포레이티드 | 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 |
| CN102731485B (zh) * | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| CN102898386B (zh) | 2011-07-27 | 2015-07-29 | 上海医药集团股份有限公司 | 喹唑啉衍生物、其制备方法、中间体、组合物及其应用 |
| CN103987700B (zh) | 2012-03-09 | 2016-08-31 | 江苏豪森药业集团有限公司 | 4-喹唑啉胺类衍生物及其用途 |
| US9550738B2 (en) * | 2012-05-14 | 2017-01-24 | Hangzhouderenyucheng Biotechnology Ltd | Bicyclic compounds as kinases inhibitors |
| CN103965120B (zh) * | 2013-01-25 | 2016-08-17 | 上海医药集团股份有限公司 | 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用 |
| TWI609012B (zh) * | 2013-04-28 | 2017-12-21 | 廣東東陽光藥業有限公司 | 氨基喹唑啉類衍生物及其鹽和使用方法 |
| CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| JP6559123B2 (ja) | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの阻害剤 |
| US10196365B2 (en) | 2014-08-15 | 2019-02-05 | Arromax Pharmatech Co., Ltd. | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof |
| WO2016055982A1 (en) * | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| KR20210137422A (ko) | 2018-09-25 | 2021-11-17 | 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 | 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도 |
-
2019
- 2019-09-24 KR KR1020217011604A patent/KR20210137422A/ko not_active Ceased
- 2019-09-24 CA CA3113241A patent/CA3113241A1/en active Pending
- 2019-09-24 CN CN201980077292.XA patent/CN113382986A/zh active Pending
- 2019-09-24 JP JP2021540390A patent/JP2022502495A/ja active Pending
- 2019-09-24 BR BR112021005513-4A patent/BR112021005513A2/pt not_active IP Right Cessation
- 2019-09-24 WO PCT/US2019/052784 patent/WO2020068867A1/en not_active Ceased
- 2019-09-24 SG SG11202102981SA patent/SG11202102981SA/en unknown
- 2019-09-24 EP EP19783859.2A patent/EP3856726A1/en not_active Withdrawn
- 2019-09-24 AU AU2019346550A patent/AU2019346550A1/en not_active Abandoned
- 2019-09-24 MX MX2021003517A patent/MX2021003517A/es unknown
-
2020
- 2020-04-17 US US16/851,767 patent/US11034672B1/en active Active
-
2021
- 2021-03-12 US US17/200,743 patent/US20220363666A1/en not_active Abandoned
- 2021-03-25 IL IL281805A patent/IL281805A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113966335B (zh) | 用于治疗癌症的egfr抑制剂 | |
| JP7108146B2 (ja) | 新規メチルキナゾリノン誘導体 | |
| JP2022537772A (ja) | 新規ｅｇｆｒ阻害剤 | |
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| CN106068262B (zh) | 喹唑啉衍生物及其制备方法和在医药上的应用 | |
| CN106795150B (zh) | 1,3,4-噻二唑化合物及其在治疗癌症中的用途 | |
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| JP2022541330A (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| JP2021176819A (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| CN113382986A (zh) | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 | |
| CN108349946B (zh) | 作为PI3Kβ抑制剂的喹喔啉和吡啶并吡嗪衍生物 | |
| DK2804863T3 (en) | NEW FORMS AND SALTS OF A dihydropyrrolo- [1,2-C] IMIDAZOLYLALDOSTERONSYNTASE OR aromatase | |
| US20230233557A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| CN108349965A (zh) | 1,3,4-噻二唑化合物及其在治疗癌症中的用途 | |
| JP2013501808A (ja) | アポトーシスを促進し、かつ転移を阻害する方法 | |
| US20030171393A1 (en) | Drugs for sex dysfunctions | |
| JP4328202B2 (ja) | 抗癌シクロペンタ［ｇ］キナゾリン化合物 | |
| JP2024542212A (ja) | 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート | |
| CN105050602B (zh) | 作为pi3激酶抑制剂的吡啶化合物 | |
| JP2024514098A5 (enExample) | ||
| JP2004521126A5 (enExample) | ||
| WO2024209717A1 (ja) | 腫瘍治療用医薬組成物 | |
| MX2015000797A (es) | Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular. | |
| WO2019081470A1 (en) | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CERTAIN SARCOMES | |
| RU2818677C2 (ru) | Ингибитор egfr для лечения рака |